During the past decade, Research Institute for Complex Issues of Cardiovascular Diseases conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 6 clinical trials were completed, i.e. on average, 35.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 5 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Research Institute for Complex Issues of Cardiovascular Diseases" #1 sponsor was "Bayer" with 4 trials, followed by "Research Institute for Complex Problems of Cardiovascular Diseases, Russia" with 4 trials sponsored, "Actelion" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Biotronik Russia" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Research Institute for Complex Issues of Cardiovascular Diseases" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Heart and Stroke Foundation of Ontario" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Research Institute for Complex Issues of Cardiovascular Diseases" are "Atrial Fibrillation" (3 trials), "Chronic Obstructive Pulmonary Disease" (2 trials), "Heart Failure" (2 trials), "Sarcopenia" (2 trials) and "Venous Thromboembolism" (2 trials). Many other conditions were trialed in "Research Institute for Complex Issues of Cardiovascular Diseases" in a lesser frequency.

Most popular intervention types in "Research Institute for Complex Issues of Cardiovascular Diseases" are "Drug" (14 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Macitentan 10 mg" (2 trials), "Neuromuscular electrical stimulation (NMES)" (2 trials), "dabigatran etexilate" (2 trials) and "BAY2433334" (1 trials). Other intervention names were less common.

The vast majority of trials in "Research Institute for Complex Issues of Cardiovascular Diseases" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Research Institute for Complex Issues of Cardiovascular Diseases". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Research Institute for Complex Issues of Cardiovascular Diseases, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Research Institute for Complex Issues of Cardiovascular Diseases, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".